Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Eltrombopag |
| Synonyms | |
| Therapy Description |
Eltrombopag is a thromobopoeitin receptor agonist that causes increased proliferation and differentiation of megakaryocytic cells and increased platelet production (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Eltrombopag | Promacta | Eltrombopag is a thromobopoeitin receptor agonist that causes increased proliferation and differentiation of megakaryocytic cells and increased platelet production (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06630221 | Phase II | Eltrombopag | Eltrombopag As a Novel Therapeutic Approach for Low-risk MDS and CMML with TET2 Mutations | Recruiting | USA | 0 |